sudok1 / iStockphoto.com
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
Disease complications, antibiotic resistance, and even death. These are just some of the consequences counterfeit drugs can have.
According to the World Health Organization (WHO), up to two billion people cannot get medicines that are crucial to their health, while many millions are at risk of falling into abject poverty due to healthcare costs they cannot afford. The organization says that this limited access to quality medicines “creates a vacuum that is too often filled by substandard and falsified products”.
The WHO estimates that one in ten medical products circulating in low and middle-income countries is either substandard or counterfeit.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
counterfeit, bigpharma, generics, counterfeit medicines, patents, World Health Organization, WHO,Alban Kang, Bird & Bird, Rouse, Gunawan Suryomurcito
